Month: February 2024

Nova Klúbburinn hf. birtir ársuppgjör fyrir 2023 eftir lokun markaða þriðjudaginn 27. febrúar. Kynningarfundur fyrir markaðsaðila og fjárfesta vegna uppgjörsins verður haldinn miðvikudaginn 28. febrúar, kl. 8:30, hjá Nova, Lágmúla 9 á 4ju hæð. Margrét Tryggvadóttir, skemmtana- & forstjóri, ásamt Þórhalli Jóhannssyni, fjármálastjóra, kynna uppgjör Nova Klúbbsins og svara fyrirspurnum. Boðið verður uppá beint streymi sem hægt verður að nálgast ásamt kynningarefni á heimasíðu Nova https://www.nova.is/fjarfestar Velkomið er að senda spurningar fyrir kynningarfundinn eða á meðan á honum stendur á netfangið fjarfestar@nova.is

BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at https://www.bbs-artebone.fi/. Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTSIn the second half of 2023, BBS made significant progress in the CE marking process of its first product, ARTEBONE® Paste, and continued ramping up production capabilities. In November, the company received confirmation from the Notified Body that the company’s quality system had received final approval, and in the same month the consultation with the Medicines...

TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Canadian GoldCamps Corp. (“Canadian GoldCamps”, or the “Company”) (CSE: CAMP) (FSE: A68) is pleased to announce that it has entered into a non-binding letter of intent dated February 13, 2024 (the “LOI”) with F3 Uranium Corp. (“F3”) whereby the Company will enter into a definitive option agreement with F3’s wholly-owned subsidiary F4 Uranium Corp. (“F4”) to earn up to a 70% interest in F4’s Murphy Lake Property (the “Property”) in the Athabasca Basin, Saskatchewan. The Property is located in the north-eastern corner of the Athabasca Basin, 30 km north-west of Orano’s McLean Lake deposits, 5 km south of ISOEnergy’s Hurricane Uranium Deposit and covers approximately 6.1 square kilometers of land. To earn an initial 50% in and to the Property,...

Enclosed is information on candidates to the Board of Directors of Eimskipafélag Íslands hf. to be elected at the Annual General Meeting 7 March 2024. Deadline for declaring candidacy has passed. According to the Company’s Articles of Association the Annual General Meeting elects five members and two alternate members for the Board of Directors and therefore the candidates will be elected to the Board of Directors without ballot at the meeting. Information on the candidates is attached. No changes were made from the previously published agenda and proposals of the meeting. The final agenda and proposals are attached. Eimskipafélag Íslands hf.’s Annual General Meeting will be held at Sundabakki 2, Reykjavík, on Thursday 7 March 2024 at 15:00 (GMT). All meeting documents are available on 2024 AGM‘s siteAttachments...

Deadline for nominations for the Board of Directors election, which will take place at the Annual General Meeting of Festi, starting at 10:00 on Wednesday 6 March 2024, has passed. The following valid nominations were received within the deadline:Guðjón Auðunsson Guðjón Reynisson Gylfi Ólafsson Hjörleifur Pálsson Margrét Guðmundsdóttir Sigurlína Ingvarsdóttir Þórður Már JóhannessonFurther information on all candidates will be published on the website https://www.festi.is/en/cc/agm-2024 no later than one week before the Annual General Meeting.

TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PX) (“Platinex” or the “Company”) is pleased to announce the completion of the name change to PTX Metals Inc. effective February 28, 2024. Management recommended the name change because ’Platinex‘ no longer accurately describes the Company’s expanded portfolio and focus on gold, copper-nickel-PGE projects. Trading will commence under the new name on Wednesday, February 28, 2024. The Company’s shares will continue to trade under the symbol PTX on the CSE, under the symbol PANXF on the OTCQB, and under 9PX on the Frankfurt Exchange. New ISIN/CUSIP numbers reflecting the name change are CA69380V1067/69380V106. Existing shareholders are able to deposit or trade their common shares in the former Company name and former CUSIP/ISIN. Effective...

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants...

Company’s latest initiative addresses growing demand for AI analytics to revolutionize patient care PLEASANTON, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) — Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” HCTI” or the “Company”), a leader in transforming healthcare through technology, today unveiled an initiative aimed at enabling healthcare organizations to harness the full potential of their organic data through Artificial Intelligence (AI) and Large Language Models (LLMs). This initiative is set against the backdrop of a rapidly expanding AI market, with Grand View Research estimating the AI in healthcare market size was $22.45 billion in 2020, and is expected to expand at a compounded annual growth rate (CAGR) of 36.4% from 2024 to 2030. Healthcare Triangle’s latest offering is poised to empower healthcare...